Quilter Plc Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Quilter Plc cut its stake in Johnson & Johnson (NYSE:JNJ) by 6.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 46,860 shares of the company’s stock after selling 3,431 shares during the quarter. Quilter Plc’s holdings in Johnson & Johnson were worth $6,777,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. IFS Advisors LLC grew its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the third quarter worth about $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the third quarter worth about $35,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on JNJ shares. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Bank of America cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Finally, Barclays upped their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Trading Up 1.3 %

NYSE JNJ opened at $157.24 on Friday. The stock has a 50-day moving average of $147.58 and a 200-day moving average of $156.00. The firm has a market cap of $378.58 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.29 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.